Feel Pro Metabolic vs Mounjaro: comparing a supplement with a licensed medicine

How Mounjaro's results were established, and why that matters for this comparison

Mounjaro works as a dual GIP and GLP-1 receptor agonist: it activates two gut-hormone pathways that govern appetite and blood-sugar regulation, and slows gastric emptying so meals feel more filling for longer. It is the only dual-agonist weight-loss medicine currently licensed in the UK. The pivotal SURMOUNT-1 trial (2,539 adults with obesity, randomised, 72 weeks) produced average weight reductions of around 20–21% at the highest dose, figures that informed NICE's appraisal of tirzepatide (TA1026), published in December 2024. In a subsequent head-to-head study (SURMOUNT-5), tirzepatide produced greater average weight loss than semaglutide 2.4 mg, and our overview of retatrutide versus Mounjaro explains how a newer generation of mechanisms compares with these established figures. These are the numbers regulators scrutinised before granting a licence. That scrutiny is absent for food supplements by design, supplements are regulated to be safe for a healthy population, not proven effective against a medical condition.

Feel Pro Metabolic typically combines ingredients such as chromium, B vitamins, and plant extracts marketed as supporting metabolism or blood-sugar balance. Chromium contributes to normal macronutrient metabolism, that is the only health claim permitted in GB, and it reflects a modest physiological role, not a weight-loss mechanism. There are no large randomised controlled trials showing clinically meaningful weight reduction from this product specifically. Comparing the two is genuinely difficult, because one has a clinical evidence base and one does not.

The regulatory and safety picture for supplements versus prescription medicine

A common assumption is that supplements are inherently safer than prescription medicines because they are sold freely. That framing gets it backwards in at least one important way. Mounjaro's safety profile was characterised across thousands of participants before the MHRA granted its licence; the side-effect pattern is known, monitored and published on the NHS medicines page for tirzepatide. Common effects are gastrointestinal (nausea, loose stools, reduced appetite) most prominent around dose increases and typically settling within a couple of weeks. Pancreatitis is a less common but serious risk; the MHRA issued a Drug Safety Update on GLP-1 medicines in January 2026 highlighting severe, persistent stomach pain radiating to the back as a reason to seek urgent medical help. Prescribers are required to assess your suitability before you start and before each dose step.

Supplements are not assessed for efficacy before sale, and post-market safety monitoring is lighter. For most people, a chromium-and-B-vitamin product carries low risk of harm, but that is different from evidence of meaningful benefit for obesity. If you have concerns about a supplement or a medicine, side effects from either can be reported at the MHRA's Yellow Card scheme. The honest conclusion: Mounjaro carries a known, characterised risk profile that was considered acceptable by regulators given its proven benefit; supplements carry fewer characterised risks largely because they have not been through the same process.

Side-by-side: what the record shows on the things people usually ask about

The table above reflects published regulatory and trial records. It is not a recommendation for either product.

If you are weighing up a supplement versus a prescription medicine, what to do next

Some people try supplements first, find limited results, and then ask whether Mounjaro is an option. Others wonder whether they could combine them. On the combining question: any supplement use should be disclosed during a consultation, because some ingredients interact with medicines or affect blood-sugar readings that prescribers monitor. Mounjaro's treatment overview page sets out the eligibility criteria: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. A lower BMI threshold can apply for some ethnic backgrounds under UK clinical guidance.

Mounjaro is not available without a prescription, and nor should it be, the dose escalation schedule exists specifically to manage tolerability, and that requires a prescriber's oversight. If you have ever wondered whether you might not meet the criteria, our page on what happens if you are rejected for Mounjaro walks through the common reasons and what your options may be. If you are curious about how it compares with other prescription approaches, our guide to GLP-1 options versus Mounjaro covers the broader landscape, and the page on metformin versus Mounjaro is useful if you have been considering that route. For cost context, the Mounjaro price comparison page explains what private treatment typically includes and why headline prices vary.

Which option is right for you depends on your health history, current BMI and what your prescriber finds appropriate, that is not a decision a product page can make. Our prescribers at nume review every consultation personally on the day it arrives. Start your free consultation if you want a clinical assessment rather than a label comparison.